Comparison of Rapid Bronchodilatory Effects of Salmeterol and Formoterol in Patients with Moderate to Severe Asthma
Backgrounds: All of Long-acting β2-agonists are beneficial in maintenance treatment of asthma but their use in relieving acute asthma attacks is not well known. The aim of this study was to compare rapid bronchodilatory effects of Salmeterol and Formoterol in patient with moderate to severe asthma.
Methods: It was a randomized, double blind, cross-over study on 60 patients with moderate to severe asthma. Patients randomly received 50 micrograms of salmeterol or 18 micrograms of formoterol and after one-week washed out period exchanged their medications. All patients undergone spirometry for four times (before receiving the drugs, as well as 3, 30 and 60 minutes after drug inhalation) and Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FVC percentage predicted value, FEV1/FVC, Peak Expiratory Flow Rate (PEFR) and PEFR percentage predicted value were measured.
Results: Both medications could significantly increase FEV1/FVC and PEFR at 3, 30 and 60 minutes after inhalation (P<0.001 compared to baseline).Three minutes after inhalation of salmeterol and formoterol, FEV1 increased by 8.7% and 12.2% respectively. Formoterol was associated with more increase in the amounts of FEV1 compared to Salmeterol.
Conclusion: This study showed that fromoterol has a more rapid onset of bronchodilating action compared with salmeterol at 3 minutes after inhalation. Both agents had significant increases in FEV1/FVC and PEFR compared to baseline with no significant differences between two drugs.
Ghaffari J, Mohammadzadeh I, Khalilian A, Rafatpanah H, Mohammadjafari H, Davoudi A. Prevalence of asthma, allergic rhinitis and eczema in elementary schools in Sari (Iran). Caspian J Intern Med 2012; 3(1):372-6.
Hospenthal MA, Peters JI. Long-acting beta (2)-agonists in the management of asthma exacerbations. Curr Opin Pulm Med 2005; 11(1):69-73.
Condemi JJ. Comparison of the efficacy of formoterol and salmetrol in patients with reversible obstructive airway disease: a multicenter, randomized open-label trial. Clin Ther 2001; 23(9):1529-41.
Bussamra MH, Stelmach R, Rodriques JC, Cukier A. A randomized comparative study of formoterol and terbutaline dry powder inhalers in the treatment of mild to moderate asthma exacerbations in the pediatric acute care setting. Ann Allergy Asthma Immunol 2009; 103(3):248-53.
Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by turbuhaler as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20(4):859-66.
Lotvall J. Pharmacological similarities and differences between beta 2- agonists. Respire Med 2000; 195(Suppl. b): S7-11.
Palmqvist M, Person G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmetrol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10(11):2484-9.
Johnson M. Pharmacology of long- acting beta- agonists. Ann Allergy Asthma Immunol 1995; 75(2): 177-9.
Sill V, Bartuschka B,Villager B, Orthand C, Domej W. Changes in specific airway resistance after powder inhalation of formoterol or salmetrol in moderate bronchial asthma. Pneumologie 1999; 53(1): 4-9.
Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 97(1):24-33.
Hermansen MN, Nielsen KG, Buchvald F, Jespersen JJ, Benqtsson T, Bisqaard H. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma. Chest 2006; 129(5):1203-9.
Self TH, Chrisman CR, Finch CK. Asthma. In koda-kimble MA, Young LA, et al. Applied therapeutice: the clinical use of drugs. 10th ed. philadelphia: Lippincott Williams & wilkins. 2012. Page 572.
Cote C, Pearle JL, Sharafkhaneh A, Spanqenthal S. Faster onset of action of formoterol versus salmetrol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther 2009; 22(1):44-9.
Copyright (c) 2015 Journal of Pharmaceutical Care
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.